Due to their exquisite biological sensitivity and specificity, monoclonal antibodies have enormous therapeutic potential to address major unmet medical needs. According to a recent Datamonitor report, the market for therapeutic monoclonal antibodies is expected to achieve a compound annual growth rate of 14% between 2006 – 2012. Growth of the small molecule therapeutics market for the same period is forecast to be only 0.6%
Theraclone’s I-STAR™ Technology provides a unique comprehensive and high throughput screen to identify functional antibodies produced naturally by human memory B cells to protect against disease-causing agents. These antibodies are optimized by natural selection for the choice of target and epitope, affinity of binding, and function. Further, we believe that these natural human antibodies will have superior stability and manufacturing properties. Using I-STAR™ we are identifying and developing novel therapeutic antibody products in the areas of infectious disease and inflammation.